In a chat with , Siddharth Sedani, Sharekhan, discusses his wealth creation ideas. Edited excerpts ET Now: Why are you proposing that investors... ...http://economictimes.indiatimes.com/markets/expert-view/why-one-should-invest-in-sun-pharma-upl-siddharth-sedani-sharekhan/articleshow/52954923.cms
MUMBAI: Drug approvals given by the US Food and Drug Administration (USFDA) to Indian companies nearly doubled year-on-year, with littleknown firms... ...http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-nods-to-indian-drugs-up-84-in-1-year/articleshow/52950279.cms
NEW DELHI: Healthcare stocks have failed to provide relief to investors in last one year. The Nifty Pharma index is down over 20 per cent from its... ...http://economictimes.indiatimes.com/markets/stocks/trends/a-bear-phase-for-pharma-pack-10-stocks-fall-up-to-40-from-highs/articleshow/52724898.cms
The National IPR (Intellectual Property Rights) policy was released on May 11. This 38-page document will give directions to the government to... ...http://www.financialexpress.com/article/fe-columnist/why-you-just-cant-have-a-one-size-fits-all-ipr-policy/282625/
By Julia Symmes Cobb and Luis Jaime Acosta BOGOTA (Reuters) - Colombia will set a new price for the Novartis cancer drug imatinib in a bid to cut... ...https://in.news.yahoo.com/colombia-set-price-novartis-cancer-drug-minister-223736337--finance.html
For Buying Imatinib & Gleevec Online...
Imatinib mesylate 400mg tablets is a...